Q2 2022 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Good morning, and welcome to the Kiniksa Pharmaceuticals Second Quarter 2022 Financial Earnings Conference Call. (Operator Instructions) And finally, I would like to advise all participants that this call is being recorded. Thank you.
I would now like to hand over to Rachel Frank, Head of IR.
Thank you, operator. Good morning, everyone, and thank you for joining Kiniksa's call to discuss our second quarter 2022 financial results and corporate update. The press release highlighting these results can be found on our website under the Investors & Media section.
As for the agenda, our CEO, Sanj K. Patel, will start with an introduction. Then Eben Tessari, our Chief Operating Officer, will review our global license agreement with Genentech for the right to develop and commercialize vixarelimab, which we announced this morning. Ross Moat, our Chief Commercial Officer, who will provide an update on our ARCALYST commercial execution. And then Mark Ragosa, our Chief Financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
